Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

Synsorb Biotech begins phase III trial for Synsorb Pk

July 25, 1997

FK-143: promising new BPH therapy

July 17, 1997

RPR launches room-temperature formulation of DDAVP

July 16, 1997

Selective alpha1a-adrenoceptor blockers described by Merck & Co.

July 10, 1997

Natural products for the treatment of BPH

July 9, 1997

Agents for BPH claimed by Merck & Co.

July 8, 1997

Hemodialyzer efficacy established in patients

July 7, 1997

Synaptic and Merck & Co. prepare selective human alpha1A-adrenoceptor antagonists

July 7, 1997

Shire acquires distribution rights for Urispas from Recordati

July 2, 1997

Joint venture formed to market RenaGel

June 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.